Efficacy of statins on sirtuin 1 and endothelial nitric oxide synthase expression: The role of sirtuin 1 gene variants in human coronary atherosclerosis

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 4, 2015, Pages 321-330

  Kilic, Ulkan ^a   Gok, Ozlem ^a   Elibol Can, Birsen ^b   Uysal, Omer ^b   Bacaksiz, Ahmet ^b  

^a ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^b BEZMIALEM VAKIF UNIVERSITY   (Turkey)

Author keywords

Coronary artery disease; Endothelial nitric oxide; Oxidative stress; Sirtuin 1 gene variant; Statin

Indexed keywords

ATORVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIRTUIN 1; ANTIOXIDANT; NOS3 PROTEIN, HUMAN; SIRT1 PROTEIN, HUMAN;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART PROTECTION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; OXIDATIVE STRESS; OXIDATIVE STRESS INDEX; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TOTAL ANTIOXIDANT STATUS; TOTAL OXIDANT STATUS; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; PHENOTYPE; TREATMENT OUTCOME;

ANTIOXIDANTS; ATORVASTATIN CALCIUM; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; ROSUVASTATIN CALCIUM; SIRTUIN 1; TREATMENT OUTCOME;

EID: 84925440227     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12362     Document Type: Article

References (53)

1. Berliner JA, Navab M, Fogelman AM et al. Atherosclerosis: Basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-96.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
3. Plehn JF, Davis BR, Sacks FM et al. Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 1999; 99: 216-23.
4. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
5. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J et al. Effects of the 3- hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 1998; 101: 2711-9.
6. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: Molecular mechanisms and clinical results. Trends Mol. Med. 2008; 14: 37-44.
7. PUBMED gene (2014) Available from: http://www.ncbi.nlm.nih.gov/gene/23411 (accessed 31 August 2014).
8. Shimoyama Y, Suzuki K, Hamajima N, Niwa T. Sirtuin 1 gene polymorphisms are associated with body fat and blood pressure in Japanese. Transl. Res. 2011; 157: 339-47.
9. Boutant M, Canto C. SIRT1 metabolic actions: Integrating recent advances from mouse models. Mol. Metab. 2013; 3: 5-18.
10. Borradaile NM, Pickering JG. NAD(+), sirtuins, and cardiovascular disease. Curr. Pharm. Des. 2009; 15: 110-7.
11. Min SW, Sohn PD, Cho SH, Swanson RA, Gan L. Sirtuins in neurodegenerative diseases: An update on potential mechanisms. Front. Aging Neurosci. 2013; 5: 53.
12. Potente M, Ghaeni L, Baldessari D et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev. 2007; 21: 2644-58.
13. Ota H, Akishita M, Eto M, Iijima K, Kaneki M, Ouchi Y. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J. Mol. Cell. Cardiol. 2007; 43: 571-9.
14. Kilic U, Gok O, Bacaksiz A, Izmirli M, Elibol-Can B, Uysal O. SIRT1 gene polymorphisms affect the protein expression in cardiovascular diseases. PLoS ONE 2014; 9: e90428.
15. Alcendor RR, Gao S, Zhai P et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res. 2007; 100: 1512-21.
16. Breitenstein A, Wyss CA, Spescha RD et al. Peripheral blood monocyte Sirt1 expression is reduced in patients with coronary artery disease. PLoS ONE 2013; 8: e53106.
17. Kilic E, Kilic U, Matter CM, Luscher TF, Bassetti CL, Hermann DM. Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase. Stroke 2005; 36: 332-6.
18. Kilic U, Bassetti CL, Kilic E, Xing H, Wang Z, Hermann DM. Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor Rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2. Neuroscience 2005; 134: 901-6.
19. Kok SH, Lin LD, Hou KL et al. Simvastatin inhibits cysteine-rich protein 61 expression in rheumatoid arthritis synovial fibroblasts through the regulation of sirtuin-1/FoxO3a signaling. Arthritis Rheum. 2013; 65: 639-49.
20. Tabuchi T, Satoh M, Itoh T, Nakamura M. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: Effect of statins on SIRT1 and microRNA-34a expression. Clin. Sci. (Lond.) 2012; 123: 161-71.
21. Vahtola E, Louhelainen M, Merasto S et al. Forkhead class O transcription factor 3a activation and Sirtuin1 overexpression in the hypertrophied myocardium of the diabetic Goto-Kakizaki rat. J. Hypertens. 2008; 26: 334-44.
22. Fulco M, Schiltz RL, Iezzi S et al. Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol. Cell 2003; 12: 51-62.
23. Kim HJ, Kim JH, Noh S et al. Metabolomic analysis of livers and serum from high-fat diet induced obese mice. J. Proteome Res. 2011; 10: 722-31.
24. Tao R, Wei D, Gao H et al. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J. Biol. Chem. 2011; 286: 14681-90.
25. van der Veer E, Nong Z, O'Neil C et al. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ. Res. 2005; 97: 25-34.
26. Littarru GP, Langsjoen P. Coenzyme Q10 and statins: Biochemical and clinical implications. Mitochondrion 2007; 7: S168-74.
27. Deichmann R, Lavie C, Andrews S. Coenzyme Q10 and statin-induced mitochondrial dysfunction. Ochsner J. 2010; 10: 16-21.
28. Kadoglou NP, Sailer N, Kapelouzou A et al. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes. Acta Diabetol. 2012; 49: 269-76.
29. Koh KK, Quon MJ, Han SH et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J. Am. Coll. Cardiol. 2010; 55: 1209-16.
30. Sato H, Carvalho G, Sato T et al. Statin intake is associated with decreased insulin sensitivity during cardiac surgery. Diabetes Care 2012; 35: 2095-9.
31. Yada T, Nakata M, Shiraishi T et al. Inhibition by simvastatin, but not pravastatin, of glucoseinduced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br. J. Pharmacol. 1999; 126: 1205-13.
32. Moutzouri E, Liberopoulos E, Mikhailidis DP et al. Disclosures comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int. J. Clin. Pract. 2011; 65: 1141-8.
33. Sun C, Zhang F, Ge X et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 2007; 6: 307-19.
34. Yano M, Matsumura T, Senokuchi T et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ. Res. 2007; 100: 1442-51.
35. Han L, Zhou R, Niu J, McNutt MA, Wang P, Tong T. SIRT1 is regulated by a PPAR{γ}-SIRT1 negative feedback loop associated with senescence. Nucleic Acids Res. 2010; 38: 7458-71.
36. Beltowski J. Statins and modulation of oxidative stress. Toxicol. Mech. Methods 2005; 15: 61-92.
37. Stein S, Schafer N, Breitenstein A et al. SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/-mice. Aging (Albany, NY) 2010; 2: 353-60.
38. Mattagajasingh I, Kim CS, Naqvi A et al. SIRT1 promotes endothelium dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA 2007; 104: 14855-60.
39. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998; 97: 2494-8.
40. Wilcox N, Subramanian RR, Sundell CL et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 2479-88.
41. Li H, Wallerath T, Munzel T, Forstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 2002; 7: 149-64.
42. Sumi D, Hayashi T, Thakur NK et al. A HMG-CoA reductase inhibitör possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects-the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 2001; 155: 347-57.
43. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-5.
44. Takizawa Y, Kosuge Y, Awaji H et al. Up-regulation of endothelial nitric oxide synthase (eNOS), silent mating type information regulation 2 homologue 1 (SIRT1) and autophagy-related genes by repeated treatments with resveratrol in human umbilical vein endothelial cells. Br. J. Nutr. 2013; 110: 2150-5.
45. Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron. Artery Dis. 2004; 15: 251-8.
46. Weyrich P, Machicao F, Reinhardt J et al. SIRT1 genetic variants associate with the metabolic response of Caucasians to a controlled lifestyle intervention-the TULIP Study. BMC Med. Genet. 2008; 9: 100.
47. Turan N, Katari S, Coutifaris C, Sapienza C. Explaining inter-individual variability in phenotype: Is epigenetics up to the challenge? Epigenetics 2010; 5: 16-9.
48. Ota H, Eto M, Kano MR et al. Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler. Thromb. Vasc. Biol. 2010; 30: 2205-11.
49. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin. Biochem. 2004; 37: 112-9.
50. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin. Biochem. 2005; 38: 1103-11.
51. Sahin-Kavakli H, Alici O, Koca C, Ilhan A, Isik B. Caffeic acid phenethyl ester decreases oxidative stress index in blunt spinal cord injury in rats. Hong Kong J. Emerg. Med. 2010; 17: 250-5.
52. Salazar LA, Hirata MH, Cavalli SA, Machado MO, Hirata RD. Optimized procedure for DNA isolation from fresh and cryopreserved clotted human blood useful in clinical molecular testing. Clin. Chem. 1998; 44: 1748-50.
53. Atsuta Y, Hamajima N. Improvement on PCR-CTPP: A SNP genotyping approach based on mismatch technique. Yi Chuan 2011; 33: 182-8.